In view of the current progress in the worldwide implementation of neonatal screening, when a neonate is genetically diagnosed with SMA, it is recommended to perform not only SMN2_CN determination, but also a more complete SMN2 characterization, including variants and if possible, structural changes [42]. Here, SMN2 is linked to proximal spinal muscular atrophy.